GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
4d
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...
The rate of vertical transmission of HIV ... treatment decisions. [12] Risks and benefits must be weighed and discussed with the patient before any treatment is initiated. Since zidovudine is the ...
The clinical features, etiology, and treatment of recurrent aphthous ... the use of certain medications, and HIV infection. The primary goals of therapy for RAU are relief of pain, reduction ...
Under US law, compounding pharmacies can make and sell patent-protected drugs that are on the FDA's shortages list in limited ...
There is a city nearby that we hide from view. Its people are of all ages, ethnicities and classes. What unites them is a ...
Retail crime is on the rise, and with it violent and abusive incidents towards shopworkers. Is the Retail Crime Action Plan ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback